Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for ...

Objectives To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease ...

圣地亚哥 - Gyre Therapeutics（纳斯达克代码：GYRE）公布第四季度营收为$27.87 million，同时给出的2025年全年营收指引低于分析师预期。 这家专注于器官纤维化治疗的商业化生物科技公司预计2025年营收在$118 million至$128 million之间。这一预期相比2024年增长11.3%至20.8%，但低于分析师预期的$135.7 million。

Reports Q4 revenue $ $27.87M consensus $23.5M…”2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and ...

An expert in connective tissue disease–associated interstitial lung disease described best approaches for rheumatologists to ...

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

After hours: March 17 at 4:49:36 PM EDT Loading Chart for MNKD ...

The UK IPF Registry has provided new insights into the evolving landscape of idiopathic pulmonary fibrosis management.

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...